Careers
Contact Us

Company
Pipeline
Disease States
Science
Investors

Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

Posted January 7, 2019 by CognitionDev

filed under: Nasdaq

In the News

Feb 20, 2020

Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

Click to view full release

Feb 19, 2020

Axsome Therapeutics to Present at Upcoming Investor Conferences

Click to view full release

Jan 22, 2020

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

Click to view full release

See All News

© 2020 Axsome Therapeutics, Inc. All rights reserved. 200 Broadway, 3rd Floor, New York, NY 10038 info@axsome.com

This modal has no inner div